InstantOne™ ELISA

The evolution of phospho ELISAs leaps forward with the efficient sensitivity and flexibility of InstantOne ELISAs.

- **Fast**: Less than 1/3 the time of traditional ELISAs
- **Easy**: 1/4 the effort with only 1 wash step
- **Flexible**: Enables the detection of total and/or phospho protein levels of a single protein up or down a pathway on a single plate
- **Sensitive**: Meeting or exceeding industry standards with only 2-3,000 cells needed
- **Compatible**: Colorimetric detection; utilizes standard plate readers
- **Complete**: Over 30 kits available, with more coming soon

HEK cells are treated with 20% FBS for 15 min prior to lysis.
Expanding Brilliance

Introducing
Brilliant Violet 605™
Brilliant Violet 650™

• Excellent signal-to-noise
• Intracellular staining compatible, non-nanocrystal
• No special buffers required
• Extensive selection
• Ready-to-use, simple integration into existing panels
• Minimal spillover

Two new additions to the Brilliant Violet™ series

Brilliant Violet 605™ and Brilliant Violet 650™ are two new additions to the Brilliant Violet™ family of novel violet laser-excitable polymers, joining Brilliant Violet 421™ and Brilliant Violet 570™.

Based on the principles of High Sensitivity Fluorescence™ developed by Sirigen, BioLegend now brings to you exceptionally bright antibody conjugates, expanding the options and utility of the violet laser in multicolor flow cytometry. With BioLegend’s commitment to accelerating research, we will be greatly expanding the number of antibody specificities for both BV605™ and BV650™ in the months to come.
Immune/Inflammatory Signaling Pathways & Dendritic Cell-T Cell Immunoregulatory Network

NEW
OptiMax™
ELISA Kits* - Microfluidics Technology
Maximum Sensitivity - Minimum Sample Use

Th17
Phenotyping Reagents

NF-κB & Inflammatory/Immune Signaling Pathways

Reporter Cell Lines & Screening Assays
TLR/NF-κB SEAPorter™ & RAW/NF-κB SEAPorter™ Cell Lines

NEW
Prom/LUCPorter™ Cell Line for IL-17A & FOXP3 Induction Studies

NEW
Nuocyte
Markers, Receptors & Molecules

Dendritic Cell Biology Reagents
DC Phenotyping Kits
DENDRITICS Abs & Reagents

NEW
Dendritics Blood B Booster® Kits: Human + Animal B Cell Immortalization

pSIVA™ Polarity Sensitive Indicator of Viability & Apoptosis

NEW
TLRs & Innate Immunity

TLRs & Innate Immunity
NLRs • RLRs • CLR

Inflammasomes
DC-T Cell Network
Signaling Pathways
Inflammation
Reporter Cell Line Systems

A to Z provider of Immune/Inflammatory Signaling Pathway Molecules & Receptors
(selected listing below)

- ACT1
- AIMP2
- AKT1
- BLT1
- Caspase-1
- CLEC1
- CLEC4E
- CLEC12A
- Clec1
- Clec4e
- Clec12a
- Dectin-2
- EBI3
- GITR
- GITRL
- KLF4
- MD-2
- MIP-3α
- MyD88
- NALP3
- NF-κB Peptide Inhibitors
- PGRP-1D
- PGRP-1E
- PGRP-S
- RAGE
- SAMHD1
- SHP-1
- SIGIRR
- SLP76
- ST2L1RL1
- ST2V
- SYK
- TBK1
- TIM3 (mouse & human)
- TLRs 1-13
- TLR Ligands/Agonists
- Tyk2
- ZAP-70
- Plus many more...

www.imgenex.com
Toll-free (888) 723-4363
Fax (858) 642-0937
Email info@imgenex.com

*OptiMax™ is a trademark of Siloam Biosciences.
Dear AAI Members, Guest Society Members, and Colleagues:

It is my great pleasure to invite you to IMMUNOLOGY 2012™ and to the historic city of Boston, Massachusetts. For your stay in Boston in May, I urge you to put aside your concern about the economy, the state of funding, and future career opportunities. Instead, take some time here to pause and marvel at the tremendous progress we are witnessing in our field. We are fortunate to be working at a time of great strides in immunology, so many that, even as densely packed as the meeting program is, it still cannot encompass every single important advance in the field. Still, no other venue can provide the broad exposure to the best and most exciting research we'll gain during the week in the Major Symposia, the Distinguished Lectures and Awards Lectures, the President's Symposium, Guest Society Symposia, NIH Institute-sponsored Symposia, the 69 Block Symposia, and the more than 1,700 poster presentations.

And there's even more than the scientific sessions making IMMUNOLOGY 2012™ unique. There are educational sessions that discuss the ins and outs of publishing, peer review, funding, and career advancement, as well as sessions focusing on the public policy issues and political developments impacting our field. We'll also have sessions to explore issues relevant to specific disciplines such as veterinary immunology and clinical immunology. There will be sessions to highlight the challenges of specific career paths—whether in academia or beyond—and the art of maintaining a work-life balance addressed by inspirational scientists. And then there are the phenomenal social events made possible through the generosity of our sponsors.

But, just as important, remember that this meeting brings you together with over 3,000 of your colleagues—individuals from across the United States, as well as all the far reaches of the globe. So spend some time finding your friends or talking with your colleagues. Look for that person whose papers you've read and always wanted to meet. Find that person you've been meaning to talk to about a potential collaboration. Stake out that interesting poster, and take advantage of the daily poster-presentation hour to meet with the presenting authors and discuss their intriguing findings.

Then, after business, there is pleasure! Boston is a beautiful, walkable city, and we are lucky that our meeting is situated in the heart of the Back Bay. No matter whether your interests are music, arts, sports, or history, you will find it worthwhile to spend some time exploring the city. Just walk right outside the door!

This is also my opportunity to thank everyone involved in planning and implementing this colossal meeting. We are fortunate to have the insight and wisdom of the AAI Program Chair Kris Hogquist, who has done a magnificent job fulfilling her responsibility for the Scientific Program. And, in turn, she is fortunate to have the dedicated and efficient AAI staff behind her to organize the myriad details necessary for a meeting of this scale. My own personal thanks go to AAI Executive Director Michele Hogan, who is the backbone of the association. Not only does she manage all of AAI's numerous activities, including overseeing the annual meeting and The Journal of Immunology, but she also "manages" the president as well!

See you in Boston!

Leslie Berg, Ph.D.,
AAI President

Leslie J. Berg, Ph.D.
AAI President

The American Association of Immunologists

Future AAI Annual Meetings

Mark Your Calendar for the Premier Annual Immunology Event!

IMMUNOLOGY 2012™
May 4–8
Boston, Massachusetts

IMMUNOLOGY 2013™
May 3–7
Honolulu, Hawaii
AAI Centennial Meeting

IMMUNOLOGY 2014™
May 2–6
Pittsburgh, Pennsylvania

IMMUNOLOGY 2015™
May 8–12
New Orleans, Louisiana
Cell Cycle Analysis on the BD FACSVerse™ System
A streamlined approach to application support.

New BD FACSuite™ software makes it easy to convert experiments to reusable assays with setup information, acquisition and analysis templates, gating strategies, and reports you can share with other BD FACSVerse™ systems. The software also provides BD predefined research assays matched with BD reagent kits for reproducible results. These assays reduce the variability of data between users and among laboratories for the same application.

Download a free application note and learn more about BD FACSuite predefined assays for apoptosis, cell cycle, cell proliferation, and cytokine detection at bdbiosciences.com/go/verse.

Simply Brilliant.

What’s Really Exciting Is What’s Behind It.

BD Biosciences
2350 Qume Drive
San Jose, CA  95131
bdbiosciences.com

Cell Cycle Analysis on the BD FACSVerse™ System
A streamlined approach to application support.

New BD FACSuite™ software makes it easy to convert experiments to reusable assays with setup information, acquisition and analysis templates, gating strategies, and reports you can share with other BD FACSVerse™ systems. The software also provides BD predefined research assays matched with BD reagent kits for reproducible results. These assays reduce the variability of data between users and among laboratories for the same application.

Download a free application note and learn more about BD FACSuite predefined assays for apoptosis, cell cycle, cell proliferation, and cytokine detection at bdbiosciences.com/go/verse.

Simply Brilliant.

What’s Really Exciting Is What’s Behind It.

BD Biosciences
2350 Qume Drive
San Jose, CA  95131
bdbiosciences.com

Class 1 Laser Product.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

BD, BD logo and all other trademarks are property of Becton, Dickinson and Company © 2011 BD 23-13664-00
Gastrointestinal Immunologist
Department of Medicine
Georgetown University

The Department of Medicine at Georgetown University seeks an outstanding MD, PhD or MD/PhD at the Assistant or Associate Professor rank.

The ideal candidate will be a clinician and/or laboratory scientist with a strong interest in translational research in gastroenterology especially with a focus on immunological disorders such as inflammatory bowel disease. The candidate will have a successful program of research demonstrated by their publication record and participation as PI or co-I on peer-reviewed extramurally funded research. The candidate will establish and lead a translational immunology program that integrates with clinical and basic science investigators within the university community and benefits from the Georgetown - Howard Universities Center for Clinical and Translational Science. Nearby federal institutions including the NIH, FDA and VA serve to enrich the academic environment while our location in the heart of the Nation's capitol offers an unparalleled social, recreational and cultural lifestyle.

Please send your cover letter and curriculum vitae by May 31, 2012 to:

Ms. Tolise Miles
Tel: 202.687.7380
E-mail: tcm9@georgetown.edu

Georgetown University is an Affirmative Action/Equal Opportunity Employer.

---

Research Focused Clinical Pathologist

The Department of Pathology at the University of Utah School of Medicine and ARUP Laboratories, Inc, is seeking a clinical pathologist with the experience and interest to develop a strong funded research program in the general area of immunology or molecular oncology. The candidate should hold an M.D. degree and be board certified/eligible in clinical pathology by the American Board of Pathology. The successful candidate must also have a strong record of scholarly activity and research experience. Academic rank will be commensurate with experience and accomplishments.

Applicants may visit the following website to apply: http://utah.peopleadmin.com/postings/12425

The University of Utah is an Affirmative Action/Equal Opportunity employer and does not discriminate based upon race, national origin, color, religion, sex, age, sexual orientation, gender identity/expression, disability, or status as a Protected Veteran. Upon request, reasonable accommodations in the application process will be provided to individuals with disabilities. To inquire about the University’s nondiscrimination policy or to request disability accommodation, please contact: Director, Office of Equal Opportunity and Affirmative Action, 201 S. Presidents Circle, Rm 135, (801)581-8365.

As a patient-focused organization, the University of Utah Health Sciences exists to enhance the health and well-being of people through patient care, research and education. Success in this mission requires a culture of collaboration, excellence, leadership, and respect. The Health Sciences Center seeks faculty and staff who are committed to the values of compassion, collaboration, innovation, responsibility, diversity, integrity, quality and trust that are integral to our mission.

The University of Utah values candidates who have experience working in settings with students from diverse backgrounds, and possess a demonstrated commitment to improving access to higher education for historically underrepresented students.

---